Viewing nowCombinationOldip HCT Tablet 5/40/12.5 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg +1 more
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.

MFDS item code 201805339 · Approved 2018.12.28 · Insurance code 640903760
Treatment of essential hypertension
This medication can help patients with essential hypertension whose blood pressure is not adequately controlled, even with combination therapy of Amlodipine and Olmesartan Medoxomil. Essential hypertension is a condition where blood pressure remains persistently high, increasing the risk of cardiovascular diseases. This medication expands blood vessels and reduces blood pressure, alleviating the burden on both the vessels and the heart. Therefore, it is used as an additional treatment option to improve hypertension when blood pressure control is difficult.
Take 1 tablet once daily with water, with or without food. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect is achieved within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation diagram. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. In particular, experience with the use of this medicine in patients aged 75 years and older is very limited; therefore, such patients should be monitored very carefully when receiving this medicine.
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.
This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to patients with allergies or hypersensitivity history to this drug or its ingredients, pregnant women, nursing mothers, patients with severe hypotension, acute heart failure, or serious renal or hepatic dysfunction. Patients with reduced blood volume or body salt may experience hypotension; therefore, their condition should be carefully monitored before administration, and appropriate measures should be taken if necessary. Patients with compromised renal function or those who have undergone kidney transplantation should have their renal function and electrolyte status checked regularly, and those with renal artery stenosis should also be monitored with caution. Patients with impaired liver function or progressive liver disease should be cautious as this medication may cause hepatic encephalopathy. Patients with heart valve diseases, obstructive coronary artery disease, primary aldosteronism, or systemic lupus erythematosus should also be administered with caution. The diuretic component of this medication may cause electrolyte imbalances, so electrolyte levels should be regularly checked through blood tests. Dizziness or drowsiness may occur during the use of this medication, so it is advisable to avoid driving or operating hazardous machinery. This medication can interact with other drugs, particularly lithium, nonsteroidal anti-inflammatory drugs (NSAIDs), and other antihypertensives; consultation with a physician or pharmacist is recommended. In case of overdose, hypotension, palpitations, and in severe cases, heart function decline may occur, necessitating immediate medical assistance. The safety and efficacy of this medication in children have not been established, and elderly patients should start with a lower dose considering renal or hepatic function declines.
Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, appetite loss, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity, anxiety, mood changes, sleep disorders, orthostatic dizziness, syncope, taste disorders, hypertonicity, sensory loss, dysesthesia, peripheral neuropathy, drowsiness, syncope, convulsions, loss of appetite, tremors, visual disturbances, reduced tears, worsening of myopia, jaundice, dizziness, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paraparesis, myalgia, bone pain, polyuria, acute renal failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, labial edema, asthenia, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal oncocytoma, acute hearing loss, lymphadenitis, acute respiratory distress syndrome
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. The storage temperature should ideally be maintained at room temperature between 1 and 30 degrees Celsius. Proper storage ensures the drug's efficacy and safety are preserved for longer.
Light yellow round film-coated tablet
28 tablets (14 tablets/PTPX2) / Carton
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg +1 more
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.